229 related articles for article (PubMed ID: 17972943)
1. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
Matsunaga T; Fukai F; Miura S; Nakane Y; Owaki T; Kodama H; Tanaka M; Nagaya T; Takimoto R; Takayama T; Niitsu Y
Leukemia; 2008 Feb; 22(2):353-60. PubMed ID: 17972943
[TBL] [Abstract][Full Text] [Related]
2. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.
Matsunaga T; Takemoto N; Sato T; Takimoto R; Tanaka I; Fujimi A; Akiyama T; Kuroda H; Kawano Y; Kobune M; Kato J; Hirayama Y; Sakamaki S; Kohda K; Miyake K; Niitsu Y
Nat Med; 2003 Sep; 9(9):1158-65. PubMed ID: 12897778
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells.
Nakagawa Y; Nakayama H; Nagata M; Yoshida R; Kawahara K; Hirosue A; Tanaka T; Yuno A; Matsuoka Y; Kojima T; Yoshitake Y; Hiraki A; Shinohara M
Int J Oncol; 2014 Apr; 44(4):1376-84. PubMed ID: 24452447
[TBL] [Abstract][Full Text] [Related]
4. A new type of antimetastatic peptide derived from fibronectin.
Kato R; Ishikawa T; Kamiya S; Oguma F; Ueki M; Goto S; Nakamura H; Katayama T; Fukai F
Clin Cancer Res; 2002 Jul; 8(7):2455-62. PubMed ID: 12114453
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of the FNIII14 Peptide Synergistically Augments the Anti-Cancer Activity of Chemotherapeutic Drugs by Activating Pro-Apoptotic Bim.
Iyoda T; Nagamine Y; Nakane Y; Tokita Y; Akari S; Otsuka K; Fujita M; Itagaki K; Takizawa Y; Orita H; Owaki T; Taira J; Hayashi R; Kodama H; Fukai F
PLoS One; 2016; 11(9):e0162525. PubMed ID: 27622612
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals.
Hu ZB; Yang GS; Li M; Miyamoto N; Minden MD; McCulloch EA
Leukemia; 1995 May; 9(5):789-98. PubMed ID: 7769841
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.
Mahlknecht U; Schönbein C
Haematologica; 2008 Mar; 93(3):443-6. PubMed ID: 18268283
[TBL] [Abstract][Full Text] [Related]
8. Ligand bound beta1 integrins inhibit procaspase-8 for mediating cell adhesion-mediated drug and radiation resistance in human leukemia cells.
Estrugo D; Fischer A; Hess F; Scherthan H; Belka C; Cordes N
PLoS One; 2007 Mar; 2(3):e269. PubMed ID: 17342203
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow fibroblast exposure to the inflammatory cytokines tumor necrosis factor-alpha and interferon-gamma increases adhesion of acute myeloid leukemia cells and alters the adhesive mechanism.
Bendall LJ; Kortlepel K; Gottlieb DJ
Exp Hematol; 1997 Feb; 25(2):132-9. PubMed ID: 9015213
[TBL] [Abstract][Full Text] [Related]
10. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
11. A fibronectin fragment induces tumor necrosis factor production of rat basophilic leukemia cells.
Kamiya S; Kawaguchi T; Hasebe S; Kamiya N; Saito Y; Miura S; Wada S; Yajima H; Katayama T; Fukai F
Biochim Biophys Acta; 2004 Nov; 1675(1-3):87-94. PubMed ID: 15535971
[TBL] [Abstract][Full Text] [Related]
12. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).
Hazlehurst LA; Damiano JS; Buyuksal I; Pledger WJ; Dalton WS
Oncogene; 2000 Sep; 19(38):4319-27. PubMed ID: 10980607
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.
Tosi P; Visani G; Ottaviani E; Manfori S; Zinzani PL; Tura S
Leukemia; 1994 Dec; 8(12):2076-82. PubMed ID: 7528855
[TBL] [Abstract][Full Text] [Related]
14. Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells.
Hu ZB; Minden MD; McCulloch EA
Leukemia; 1995 Oct; 9(10):1667-73. PubMed ID: 7564507
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
16. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
17. The association of up-regulation of X-linked inhibitor of apoptosis protein with cell adhesion-mediated drug resistance in U937 cells.
Wang X; Wang C; Qin YW; Yan SK; Gao YR
Hematol Oncol; 2008 Mar; 26(1):21-6. PubMed ID: 17721914
[TBL] [Abstract][Full Text] [Related]
18. Antiadhesive sites present in the fibronectin type III-like repeats of human plasma fibronectin.
Miura S; Kamiya S; Saito Y; Wada S; Hayashi R; Taira J; Kodama H; Yajima H; Ueki M; Fukai F
Biol Pharm Bull; 2007 May; 30(5):891-7. PubMed ID: 17473431
[TBL] [Abstract][Full Text] [Related]
19. [Detection of the resistance to Ara-C blast cells in acute myeloid leukemia using flow cytometry].
Lacombe F; Belloc F; Dumain P; Puntous M; Cony-Makhoul P; Bernard P; Boisseau MR; Reiffers J
Bull Cancer; 1995; 82(5):349-56. PubMed ID: 7626842
[TBL] [Abstract][Full Text] [Related]
20. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
